Skip to content
HowShorted

KalVista Pharmaceuticals, Inc. short interest in 2022

In 2022, KalVista Pharmaceuticals, Inc.'s disclosed short interest ran from 4.33% of shares outstanding on 14 Jan 2022 to 9.69% on 30 Dec 2022, a change of +5.36 percentage points. The year's high was 10.36% on 30 Sep 2022 and its low 3.56% on 14 Apr 2022, averaging 7.09% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.70 days on 15 Sep 2022. Full history: KalVista Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for KalVista Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
4.33% (14 Jan 2022)
End of year
9.69% (30 Dec 2022)
Change
+5.36 pp
High
10.36% (30 Sep 2022)
Low
3.56% (14 Apr 2022)
Average
7.09%
Highest days to cover
15.70 (15 Sep 2022)
SEC filings marked
8

Every report in 2022

KalVista Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20224.33%6.53
31 Jan 20224.98%4.89
15 Feb 20224.72%4.99
28 Feb 20225.30%6.94
15 Mar 20225.39%8.1910-Q filed, results (8-K)
31 Mar 20224.42%6.53
14 Apr 20223.56%3.21
29 Apr 20223.73%5.51
13 May 20225.13%3.58
31 May 20225.52%2.98
15 Jun 20228.70%5.13
30 Jun 20227.27%4.76
15 Jul 20227.51%11.3010-K filed, results (8-K)
29 Jul 20227.68%11.87
15 Aug 20228.35%13.65
31 Aug 20229.56%10.33
15 Sep 20229.98%15.7010-Q filed, results (8-K)
30 Sep 202210.36%15.42
14 Oct 20229.33%1.77
31 Oct 20229.25%5.50
15 Nov 20228.45%7.34
30 Nov 20228.43%11.02
15 Dec 20228.44%8.4110-Q filed, results (8-K)
30 Dec 20229.69%6.90

See also: KalVista Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.